Case Report

False-positive inflammatory change mimicking glioblastoma multiforme under 5-aminolevulinic acid-guided surgery: A case report

Koji Omoto, Ryosuke Matsuda, Ichiro Nakagawa, Yasushi Motoyama, Hiroyuki Nakase

Department of Neurosurgery, Nara Medical University, Kashihara, Japan

E-mail: Koji Omoto - koujiplain128@gmail.com; *Ryosuke Matsuda - cak93500@pop02.odn.ne.jp; Ichiro Nakagawa - nakagawa@naramed-u.ac.jp; Yasushi Motoyama - myasushi@naramed-u.ac.jp; Hiroyuki Nakase - nakasehi@naramed-u.ac.jp

*Corresponding author

Received: 13 December 17  Accepted: 02 January 18  Published: 23 February 18

Abstract

Background: 5-aminolevulinic acid (5-ALA)–guided surgery is one of the gold standard perioperative modalities for maximum resection of malignant gliomas. However, it should be noted that 5-ALA fluorescence does not definitively indicate the presence of malignant tumor cells.

Case Description: We report a rare case of false-positive lesion mimicking glioblastoma multiforme (GBM) under 5-ALA-guided surgery. A 44-year-old woman presented with persistent headache and flickering in her eyes. Magnetic resonance imaging showed enhanced lesion with perifocal edema in the left occipital lobe. We performed 5-ALA-guided surgery for the lesion, during which strong fluorescence was observed, but evaluation of the intraoperative frozen section revealed only inflammatory cells. We concluded the tumor resection once adequate decompression had been achieved, and made the final pathological diagnosis of inflammatory change following an unknown infection.

Conclusion: Neurosurgeons should be aware of false-positive lesions mimicking GBM under 5-ALA guided surgery.

Key Words: 5-aminolevulinic acid, glioblastoma, inflammatory disease

INTRODUCTION

5-aminolevulinic acid (5-ALA)–guided surgery is one of the gold standard perioperative modalities for maximum resection of malignant gliomas. Recent studies of malignant gliomas have demonstrated that resection under 5-ALA-guided surgery leads to significantly improved progression-free survival[15] and better overall survival.[1]

5-ALA is in itself not fluorescent but serves as the metabolic precursor of heme in the heme biosynthetic pathway where it is metabolized into endogenous fluorescent protoporphyrin IX (PpIX). Consequently, oral intake of 5-ALA results in accumulation of intracellular PpIX. Exposure to blue light at 405 nm wavelength causes excitation of the PpIX, allowing it to become visible as

How to cite this article: Omoto K, Matsuda R, Nakagawa I, Motoyama Y, Nakase H. False-positive inflammatory change mimicking glioblastoma multiforme under 5-aminolevulinic acid-guided surgery: A case report. Surg Neurol Int 2018;9:49. http://surgicalneurologyint.com/False-positive-inflammatory-change-mimicking-glioblastoma-multiforme-under-5-aminolevulinic-acid-guided-surgery-A-case-report/
red fluorescence. Because 5-ALA–guided surgery depends not on the tumor itself but rather on the fluorescence of accumulated intracellular PpIX, neurosurgeons should be aware of false-positive findings that can result in higher accumulations of PpIX. For example, false-positives have occurred with radiation necrosis,[7,10] multiple sclerosis,[11] abscess,[17] and cerebral infarction.[2] In this case report, we aimed to discuss the false-positive inflammatory change mimicking glioblastoma multiforme (GBM) that may appear under 5-ALA fluorescence, and particularly, the careful use of 5-ALA-guided surgery.

**CASE DESCRIPTION**

A 44-year-old woman with no history presented at a local hospital with persistent headache and flickering in her eyes. Computed tomography (CT) of the head revealed a small amount of hemorrhage with strong perifocal edema in the left occipital lobe. She was eventually transferred to our hospital for further treatment. Contrast-enhanced magnetic resonance imaging (MRI) showed heterogeneous enhancement in the left occipital lobe [Figure 1]. No primary tumor was found with enhanced CT of the body. Blood examination showed normal tumor markers, C-reactive protein, and white blood cells. Our preoperative diagnosis was glioblastoma. We administered 5-ALA (Nobelpharma, Tokyo, Japan) at 20 mg/kg prior to her procedure, and biopsied the internal lesion that appeared as red fluorescence under blue light (ZEISS OPMI PENTERO 900) [Figure 2]. However, intraoperative frozen section revealed the presence of only inflammatory cells and the absence of malignant tumor cells. During resection, strong 5-ALA fluorescence was continuously observed on the surface of and inside the lesion.

We performed a lesionectomy with enhanced lesion to confirm the pathological diagnosis and reduce edema in the brain. We did not resect the peritumoral lesion despite the vague fluorescence. After the surgical resection, the patient exhibited only right upper quadrant hemianopia. Histopathological examination with hematoxylin-eosin (HE) staining revealed [Figure 3a] signs of infection, inflammation characterized by the accumulation of neutrophils, lymphocytes, and macrophages positive for CD68 in immunohistochemistry (IHC) [Figure 3b]. Gram, PAS, Grocott, and Ziehl–Neelsen staining demonstrated absence of pathogens in the lesion. We determined that the cause of the intraoperative fluorescence was inflammatory change and ruled out GBM [Figure 3c]. The patient did not require additional treatment and was able to return to her normal activities. Follow-up MRI at 30 months showed no recurrence and an unchanged postoperative cavity [Figure 4]. Because specific enzymes or transporters in the porphyrin-biosynthesis pathway are factors in 5-ALA-induced false-positive fluorescence, we performed an analysis with IHC and found high expression of peptide transporter 1 (PEPT1) [Figure 3d] and low expression of ATP-binding cassette transporter G2 (ABCG2) [Figure 3e] and ferrochelatase (FECH) [Figure 3f].

**DISCUSSION**

5-ALA–guided surgery for resection of malignant gliomas is a standard surgical procedure at many neuro-oncological centers. Therefore, it is crucial for neurosurgeons to understand the mechanisms involved in intraoperative 5-ALA fluorescence. GBM is a locally invasive tumor that has poor prognosis despite treatment. The outcomes for patients with GBM can vary depending on the individual characteristics of the patient and the specific tumor. Patient age, Karnofsky Performance Status (KPS) score, and extent of resection are the most significant clinical predictors of survival for patients with GBM.[8,13] In addition, Stummer et al. reported that 5-ALA-fluorescence-guided surgery enables more comprehensive resection and leads to improved progression-free survival in patients with malignant glioma.[15]

However, it should be noted that 5-ALA fluorescence does not definitively indicate the presence of malignant...
tumor cells. Researchers have reported cases of nontumorous conditions mimicking GBM by displaying high 5-ALA fluorescence intraoperatively, such as radiation necrosis, multiple sclerosis, abscess, and cerebral infarction. In such cases, surgical resection of the strongly fluorescent area should be considered to prevent unnecessary neurological deficits.

5-ALA is a precursor molecule in the heme biosynthetic pathway, where its metabolism induces the production of PpIX. Ferrous iron is added to PpIX, a reaction catalyzed by FECH, to form nonfluorescent heme. The previous study mentioned that FECH has been known to cause enzyme-mediated intracellular accumulation of PpIX in human glioma cells and in bladder cancer. 5-ALA-induced PpIX production in gastric cancer has also been determined by high expression of PEPT1. In addition, ABCG2 has a critical role in 5-ALA-photodynamic diagnosis of and therapy in human brain tumor.

In malignant tumor cells, the key enzymes and transporters in the porphyrin-biosynthesis pathway of 5-ALA metabolism are different from those of other types of tumors. However, their presence has been reported with nontumorous disease. Most likely, the mechanisms responsible for fluorescence in nontumorous conditions are distinct activated enzyme or transporter expression patterns associated with porphyrin-biosynthesis pathways similar to those of tumor cells.

In our patient, the occurrence of intraoperative fluorescence can be explained by the increased expression of PEPT1 and the suppressed expression of ABCG2 and FECH found with IHC. This reaction may be caused by the presence of an infection, which triggers an immune response leading to an invasion of microglia, neutrophils, macrophages, and lymphocytes. Macrophages, activated lymphocytes, and neutrophils cause increased accumulation of PpIX when incubated with 5-ALA.

We confirmed the presence of macrophages with positive stain by IHC in CD68 as well as the presence of lymphocytes with CD3 and 20 (figure not shown). We concluded that inflammatory change resulting from an infection led to the invasion of microglia, neutrophils, macrophages, and lymphocytes that caused increased expression of PEPT1 and suppressed expression of ABCG2 and FECH, thereby increasing the intracellular accumulation of PpIX.

**CONCLUSION**

This case report presents the first description of 5-ALA-induced fluorescence with IHC caused by inflammatory change after an unknown infection. 5-ALA-guided surgery is a useful modality for the removal of brain tumors. However, false-positives can occur with accumulation of PpIX, as in our patient, which can lead to extensive removal and risk of critical postoperative complications. It is important to use caution with 5-ALA-guided surgery for tumor resection.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 2013;72:915-20.
2. Behling F, Hennersdorf F, Bornemann A, Tatagiba M, Skardelly M. 5-aminolevulinic acid accumulation in a cerebral infarction mimicking high-grade glioma. World Neurosurg 2016;92:585-8.
3. Bissonnette R, Zeng H, McLean DJ, Korbelik M, Lui H. Oral aminolevulinic acid induces protoporphyrin ix fluorescence in psoriatic plaques and peripheral blood cells. Photochem Photobiol 2001;74:339-45.
4. Fujino M, Nishio Y, Ito H, Tanaka T, Li XK. 5-aminolevulinic acid regulates the inflammatory response and alloanyme reaction. Int Immunopharmacol 2016;37;71-8.
5. Hagya Y, Endo Y, Yonemura Y, Takahashi K, Ishizuka M, Abe F, et al. Pivotal roles of peptide transporter pept1 and atp-binding cassette (abc) transporter abcg2 in 5-aminolevulinic acid (ala)-based photocytotoxicity of gastric cancer cells in vitro. Photodiagnosis Photodyn Ther 2012;9:204-14.
6. Ishikawa T, Kajimoto Y, Inoue Y, Ikegami Y, Kuroiwa T. Critical role of abcg2 in ala-photodynamic diagnosis and therapy of human brain tumor. Adv Cancer Res 2015;125:197-216.
7. Kamp MA, Felsberg J, Sadat H, Kuzibaev J, Steiger HJ, Rapp M, et al. S-ala-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta Neurochir (Wien) 2015;157:207-13.
8. Lacroix M, Abi-Said D, Fournier DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
9. Miyake M, Ishii M, Kawashima K, Kodama T, Sugano K, Fujimoto K, et al. siRNA-mediated knockdown of the heme synthesis and degradation pathways: Modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. Photochem Photobiol 2009;85:1020-7.
10. Miyatake Y, Kuroiwa T, Kajimoto Y, Miyashita M, Tanaka H, Tsuji M. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: Case report. Neurosurgery 2007;61:1101-3.
11. Nabavi A, Thur H, Zontzas B, Pietsch T, Lanfermann H, Pichlmayer U, et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: A phase ii study. Neurosurgery 2009;65:1070-6.
12. Rittenhouse-Diakun K, Van Leengoed H, Morgan J, Hryhorenko E, Paszkiewicz G, Whitaker JE, et al. The role of transferrin receptor (cd71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ala). Photochem Photobiol 1995;61:523-8.
13. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8.
14. Sharma S, Jajoo A, Dube A. 5-aminolevulinic acid-induced protoporphyrin-ix accumulation and associated photoxicity in macrophages and oral cancer cell lines. J Photochem Photobiol 2007;88:156-62.
15. Stummer W, Pichlmayer U, Meinl T, Wiestler OD, Zanella F, Reulen HJ. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase iii trial. Lancet Oncol 2006;7:392-401.
16. Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, Nambu E, et al. Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 2011;104:798-807.
17. Voellgier B, Klein J, Mawrin C, Firsching R. 5-aminolevulinic acid (5-ala) fluorescence in infectious disease of the brain. Acta Neurochir (Wien) 2014;156:1977-8.